吉西他滨联合卡培他滨治疗难治性乳腺癌的临床研究  

Clinical observation on gemcitabine plus capecitabine in refractory metastatic breast cancer

作　　者：毕益明[1] 付艳[1] 陈秀芳[1] 郑东星[1] 李强[1] 张素美[1] 王淑燕[1] 

机构地区：[1]山东省滨州市人民医院肿瘤二科,山东滨州256610

出　　处：《现代肿瘤医学》2010年第10期1970-1972,共3页Journal of Modern Oncology

摘　　要：目的:观察吉西他滨联合卡培他滨治疗难治性乳腺癌的疗效和不良反应。方法:37例难治性乳腺癌患者,应用吉西他滨联合卡培他滨,持续应用至疾病进展或出现不能耐受的不良反应。并按WHO标准评价疗效及不良反应,随访生存情况。结果:在37例可评价的患者中,CR 3例,PR 12例,SD 13例,PD 9例。RR为40.54%;DCR为75.68%。中位TTP为9个月(95%CI:6.115-11.885M);中位OS为15个月(95%CI:10.663-19.337M)。主要不良反应为骨髓抑制,其次为胃肠道反应。结论:吉西他滨联合卡培他滨治疗难治性乳腺癌有较好的疗效,不良反应可以耐受。Objective：To evaluate the efficacy and side effects of gemcitabine plus capecitabine for refractory patients with metastatic breast cancer.Methods：Thirty-seven patients with metastatic breast cancer were treated by gemcitabine plus capecitabine.Response and side effect were evaluated by WHO standard.Results：Among 37 patients,3 cases achieved CR,12 PR,13 SD,9 PD.The remission rate was 40.54%,and total disease control rate was 75.68%,median time to progression was 9（95%CI：6.115-11.885）months and median overall survival time was 15（95%CI：10.663-19.337）months.The major adverse events were bone marrow suppression and gastrointestinal side effect.Conclusion：Gemcitabine plus capecitabine is an effective and well tolerate regimen for refractory patients with metastatic breast cancer.

关 键 词：吉西他滨 卡培他滨 化疗 难治性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]